WBA Quote, Financials, Valuation and Earnings

CVS Health has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of 1.68%. Walgreens Boots Alliance's return on equity of -46.98% beat CVS Health's return on equity of 6.12%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 14.03%. On the other hand CVS Health has an analysts' consensus of $73.26 which suggests that it could grow by 5.39%. Given that Walgreens Boots Alliance has higher upside potential than CVS Health, analysts believe Walgreens Boots Alliance is more attractive than CVS Health.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison CVS Health has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.622%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.28%. CVS Health offers a yield of 3.83% to investors and pays a quarterly dividend of $0.67 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are smaller than CVS Health quarterly revenues of $97.7B. Walgreens Boots Alliance's net income of -$2.9B is lower than CVS Health's net income of $1.6B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while CVS Health's PE ratio is 18.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 0.24x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of 15.24%. Walgreens Boots Alliance's return on equity of -46.98% beat Johnson & Johnson's return on equity of 19.98%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 14.03%. On the other hand Johnson & Johnson has an analysts' consensus of $169.87 which suggests that it could grow by 11.96%. Given that Walgreens Boots Alliance has higher upside potential than Johnson & Johnson, analysts believe Walgreens Boots Alliance is more attractive than Johnson & Johnson.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.28%. Johnson & Johnson offers a yield of 3.27% to investors and pays a quarterly dividend of $1.24 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are larger than Johnson & Johnson quarterly revenues of $22.5B. Walgreens Boots Alliance's net income of -$2.9B is lower than Johnson & Johnson's net income of $3.4B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 26.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of -117.16%. Walgreens Boots Alliance's return on equity of -46.98% beat Moderna's return on equity of -29.09%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 14.03%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 98.66%. Given that Moderna has higher upside potential than Walgreens Boots Alliance, analysts believe Moderna is more attractive than Walgreens Boots Alliance.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.28%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are larger than Moderna quarterly revenues of $956M. Walgreens Boots Alliance's net income of -$2.9B is lower than Moderna's net income of -$1.1B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of 5.5%. Walgreens Boots Alliance's return on equity of -46.98% beat UnitedHealth Group's return on equity of 14.34%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 14.03%. On the other hand UnitedHealth Group has an analysts' consensus of $635.32 which suggests that it could grow by 5.98%. Given that Walgreens Boots Alliance has higher upside potential than UnitedHealth Group, analysts believe Walgreens Boots Alliance is more attractive than UnitedHealth Group.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.293%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.28%. UnitedHealth Group offers a yield of 1.4% to investors and pays a quarterly dividend of $2.10 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are smaller than UnitedHealth Group quarterly revenues of $100.8B. Walgreens Boots Alliance's net income of -$2.9B is lower than UnitedHealth Group's net income of $5.5B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while UnitedHealth Group's PE ratio is 38.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 1.39x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.